J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in? - FiercePharma

Submitted by Anonymous (not verified) on Tue, 09/10/2019 - 14:30

J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in?  FiercePharmaJohnson & Johnson wants to change the antidepression market with its ketamine-derivative Spravato, and new data showing the drug topped placebo in ...